A5051951830- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Nutrition, Genetics, and Disease
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Gene expression and cancer classification
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Reproductive Biology and Fertility
- Cancer Cells and Metastasis
- COVID-19 and healthcare impacts
- Multiple and Secondary Primary Cancers
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Ovarian function and disorders
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- COVID-19 Clinical Research Studies
- Cytokine Signaling Pathways and Interactions
- Chronic Lymphocytic Leukemia Research
Azienda Ospedaliero-Universitaria di Modena
2025
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2020-2024
Hospital Clínic de Barcelona
2020-2024
Breast Cancer Research Foundation
2023-2024
Biomedical Research Institute
2023-2024
Ospedale Policlinico San Martino
2016-2023
Universitat de Barcelona
2023
Target (United States)
2023
Solti
2021-2022
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical molecular features HER2-low BC yet to be elucidated. Here, we collected retrospective clinicopathological PAM50 data from 3,689 patients disease made following observations. First, proportion was higher HR-positive (65.4%) than triple-negative (TNBC, 36.6%). Second, within disease, luminal-related...
The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this detects most mutations in BC. This information critical as clinicians using other genomic assays indicate alpelisib.Data from 6338 BC was explored across 10 publicly available studies. primary objective evaluate proportion distribution of...
Both clinical and genomic data independently predict survival treatment response in early-stage HER2-positive breast cancer. Here we present the development validation of a new HER2DX risk score, pathological complete (pCR) both based on 27-gene expression plus feature-based classifier.HER2DX is supervised learning algorithm incorporating tumour size, nodal staging, 4 gene signatures tracking immune infiltration, cell proliferation, luminal differentiation, HER2 amplicon, into single score....
Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a standpoint, immune infiltration plays crucial role in TNBC prognosis. Currently, there is lack of genomic tools aiding treatment decisions for TNBC. This study aims to assess the effectiveness B-cell/immunoglobulin signature (IGG) alone, or combination with tumor burden, predicting prognosis response patients
The novel coronavirus disease 2019 (COVID-19) shows a wide spectrum of clinical presentations, severity, and fatality rates. reason older patients males show increased risk severe death remains uncertain. Sex hormones, such as estradiol, progesterone, testosterone, might be implicated in the age-dependent sex-specific severity COVID-19. High testosterone levels could upregulate transmembrane serine protease 2 (TMPRSS2), facilitating entry acute respiratory syndrome (SARS-CoV-2) into host...
During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have reported to experience a more severe syndrome; moreover, there are concerns of potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis.Between 6 16 May 2020, 22-item survey was sent Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks patients receiving ICIs, attitudes towards their management.The...
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with emtansine (T-DM1). However, can have considerable toxicities, and right treatment sequence unknown. Biomarkers to guide use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels ERBB2 mRNA expression according HER2DX standardized assay associated response survival following T-DM1. low, medium, high groups, overall...
Abstract Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET); however, critical questions remain unanswered such as which assay or statistical method use. Here, we obtained paired plasma samples at baseline week 4 in 45 consecutive patients with advanced breast cancer treated CDK4/6i+ET. ctDNA was detected 96% of cases using the 74-gene Guardant360 assay. A variant allele fraction ratio...
In the absence of identified therapeutic targets, chemotherapy is main systemic treatment option for triple-negative breast cancer (TNBC). The achievement a pathological complete response (pCR) after neoadjuvant leads to good outcome, whereas patients not achieving pCR are at high risk relapse. Various trials have evaluated inclusion platinum in regimens TNBC, leading non-univocal results. panel Italian Association Medical Oncology (AIOM) Guidelines on Breast Cancer developed clinical...
Abstract Background Neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) are sometimes used to shrink hormone receptor-positive (HoR+)/HER2-negative breast cancer (BC) before surgery. These treatments can change the tumor on a molecular level, but impact patient outcomes remains unclear. There is also lack of detailed comparison between changes induced by both therapies. Methods We studied 186 patients with early-stage BC treated at our Institution either NACT or NET. Changes in...
The phase III GIM2 trial showed improved disease-free survival (DFS) and overall (OS) with adjuvant dose-dense (DD) as compared standard-interval (SI) chemotherapy in women node-positive early-stage breast cancer (BC). This exploratory analysis aimed to investigate the benefit of different schedules according body mass index (BMI) this trial.
Breast cancer is still the most frequent diagnosed in women aged ≤40 years and primary cause of death this age group. The management these patients needs a dedicated approach involving multidisciplinary team that takes into account their treatment survivorship issues. present review aims to provide perspective on many challenges associated with young early breast cancer. We will focus standard (neo)adjuvant treatment, highlighting paucity age-specific results about available genomic...